帕利培酮合用艾司西酞普兰治疗精神分裂症阴性症状的观察

摘要

目的 探讨帕利培酮合用艾司西酞普兰对精神分裂症阴性症状的疗效和安全性.方法 将84例以阴性症状为主的精神分裂症患者随机分为观察组与对照组,观察组给予帕利培酮合用艾司西酞普兰治疗,对照组单用帕利培酮,疗程12周.于治疗前及治疗后第4、8、12 周末用阳性与阴性症状量表(PANSS)评定疗效,采用不良反应量表(TESS)评定不良反应.结果 观察组总有效率为85.7%,对照组为64.3%,2组比较差异有统计学意义(P<0.05).与治疗前比较,第4、8、12周末2组PANSS总分、阳性因子分、阴性因子分、一般精神病理分显著改善,差异有统计学意义(P<0.05).第8、12周末,观察组PANSS总分、阴性因子分与对照组比较差异有统计学意义(P<0.05).治疗12周末,观察组情感迟钝、情绪退缩、情感交流障碍、被动/淡漠性社交退缩评分与对照组比较差异有统计学意义(P<0.05).2组TESS评分比较差异无统计学意义(P>0.05).结论 采用帕利培酮合用艾司西酞普兰治疗精神分裂症阴性症状疗效确切,安全性好.%Objective To investigate paliperidone combined with escitalopram on negative symptoms of schizophrenia , test the efficacy and safety. Methods 84 patients with predominantly negative symptoms of schizophrenia were randomly divided into study group and control group , study group with paliperidone combined escitalopram treatment , the control group only used paliperidone for 12 weeks. Before treatment and after treatment of 4th, 8th, 12th weekends with positive and negative symptoms scale (PANSS) assessment of efficacy. The application of side reaction scale (TESS) assessment of side effects. Results The total effective rate in treatment group was 85. 7% , which was 64. 3% in control group , there was significant differences ( P <0. 05). The same group before and after treatment , 4th, 8th, 12th over the weekend , the study group negative factor difference than before treatment was statistically significant ( P <0. 05) , 4th,8th, 12th over the weekend , the control group negative factor scores was statistically significant differences compared with those before treatment (P < 0.05). Comparison of the two groups : 8th, 12th over the weekend, the study group PANSS , negative factor difference compared with the control group had statistical significance ( P < 0. 05 ). No significant differences in TESS score ( P > 0. 05 ). Conclusion The paliperidone combined escitalopram treatment of negative symptoms of schizophrenia curative effect is good and safe.